Key clinical point: Adding atezolizumab to neoadjuvant chemo didn’t significantly improve pCR rates in women with TNBC, but patients are still being followed for the primary endpoint of EFS.

Major finding: A pCR rate: 43.5% vs. 40.8% with vs. without atezolizumab; OR, 1.11.

Study details: The open-label multicenter NeoTRIPaPDL1 study of 208 patients.

Disclosures: This study was sponsored by Roche and Celgene. Dr. Gianni has been an advisor and/or consultant for numerous pharmaceutical companies. He has received support for research from Daiichi Sankyo, Zymeworks, and Revolution Medicines and is a co-inventor on a patent for PD-L1 expression in anti-HER2 therapy.